Petri dish)

Research and Development

Current R&D Areas of Focus in Transplantation

We currently have four active clinical programs focused on addressing major complications following kidney and stem cell transplantation.

Solid Organ Transplantation

Compound Number Investigational Indication Mode of Action Stage Trial Name
CSL842  AMR in Kidney transplant recipients  C1 - Inhibitor Phase III Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as Adjunctive Treatment For Refractory Antibody-Mediated Rejection in Adult Renal Transplant Recipients (ARMOR) - Learn More
CSL300  AMR in Kidney transplant recipients  Anti-IL-6    monoclonal antibody Phase III Interleukin 6 blockade Modifying Antibody-mediated Graft Injury and eGFR decline (IMAGINE) - Learn More

Stem Cell Transplantation

Compound Number Investigational Indication Mode of Action  Stage Trial Name
CSL964  GvHD Prevention  Alpha-1 Antitrypsin Phase II/III The Safety and Efficacy of Alpha-1 Antitrypsin for the Prevention of Graft-Versus-Host-Disease in Patients Receiving Hematopoeitic Cell Transplant (MODULAATE) - Learn More
CSL964  GvHD Treatment (collaboration with BMT CTN)  Alpha-1 Antitrypsin  Phase III Treatment of GVHD in Hematopoietic Stem Cell Transplant Recipients Using AAT Plus Corticosteroids Compared with Corticosteroids Alone (BMT CTN 1705)  - Learn More